<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-title>BMC Psychiatry</journal-title><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">1310608</article-id><article-id pub-id-type="publisher-id">1471-244X-5-44</article-id><article-id pub-id-type="doi">10.1186/1471-244X-5-44</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Carey</surname><given-names>Paul D</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pcarey@sun.ac.za</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Vythilingum</surname><given-names>Bavanisha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bv@sun.ac.za</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Seedat</surname><given-names>Soraya</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sseedat@sun.ac.za</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Muller</surname><given-names>Jacqueline E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jemuller@sun.ac.za</email></contrib><contrib id="A5" contrib-type="author"><name><surname>van Ameringen</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>vanamer@mcmaster.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Stein</surname><given-names>Dan J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>djs2@sun.ac.za</email></contrib></contrib-group><aff id="I1"><label>1</label>MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa</aff><aff id="I2"><label>2</label>Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2005</year></pub-date><volume>5</volume><fpage>44</fpage><lpage>44</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/5/44"/><history><date date-type="received"><day>25</day><month>11</month><year>2005</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Carey et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Carey et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Carey
               D
               Paul
               
               pcarey@sun.ac.za
            </dc:author><dc:title>
            Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>BMC Psychiatry 5(1): 44-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-244X(2005)5:1&#x0003c;44&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-244X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><related-article related-article-type="corrected-article" vol="5" page="5" id="N0x9642260N0x9d34e80" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="15667657" ext-link-type="pubmed"/></article-meta></front><body><p>The comment in the introduction of our article [<xref ref-type="bibr" rid="B1">1</xref>] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [<xref ref-type="bibr" rid="B2">2</xref>].</p><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/5/44/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>PD</given-names></name><name><surname>Vythilingum</surname><given-names>B</given-names></name><name><surname>Seedat</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>JE</given-names></name><name><surname>van</surname><given-names>AM</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name></person-group><article-title>Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]</article-title><source>BMC Psychiatry</source><year>2005</year><volume>5</volume><fpage>5</fpage><pub-id pub-id-type="pmid">15667657</pub-id><pub-id pub-id-type="doi">10.1186/1471-244X-5-5</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richelson</surname><given-names>E</given-names></name><name><surname>Souder</surname><given-names>T</given-names></name></person-group><article-title>Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds</article-title><source>Life Sci</source><year>2000</year><volume>68</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">11132243</pub-id><pub-id pub-id-type="doi">10.1016/S0024-3205(00)00911-5</pub-id></citation></ref></ref-list></back></article>


